Natixis Advisors L.P. Has $22.65 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Natixis Advisors L.P. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 279,620 shares of the biopharmaceutical company’s stock after buying an additional 36,711 shares during the quarter. Natixis Advisors L.P.’s holdings in Gilead Sciences were worth $22,652,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Tompkins Financial Corp lifted its holdings in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the period. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at $26,000. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Rakuten Securities Inc. acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $33,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.8 %

GILD stock opened at $64.78 on Monday. The firm has a 50-day moving average price of $70.55 and a 200-day moving average price of $75.78. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $80.66 billion, a P/E ratio of 179.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.37 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.75%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. Maxim Group dropped their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. TD Cowen cut their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Finally, Mizuho decreased their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and an average price target of $83.69.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.